Biosynthesis of Naphthoquinone Pigments by Fungi of the Genus Fusarium

Applied Biochemistry and Microbiology - We studied the biosynthesis of colored naphthoquinone metabolites by Fusarium decemcellulare, F. graminearum, and F. bulbigenum fungi. Depending on the...     

Allozymic, morphological, and phenological diversity in cultivatedLuffa acutangula (Cucurbitaceae) from China, Laos, and Nepal, and Allozyme Divergence betweenL. acutangula andL. Aegyptiaca

The immature fruits of domesticated Luffa acutangula (L.) Roxb. are a common vegetable in Asia and India. To learn more about traditional cultivars, accessions were collected from southern Yunnan Province of China, northern Laos, and southeastern Nepal, and assessed for various parameters of genetic diversity. The size and shape of the fruits and seeds varied considerably. A form that we found cultivated only in Nepal bore clusters of small fruits that are produced by hermaphrodite flowers. Plants produced male flowers first, and the first node to bear flowers varied from the second to the twenty-seventh. Twenty-nine allozyme loci were assayed. Within L. acutangula one allozyme locus was polymorphic. Luffa acutangula andL. aegyptiaca are fixed for different alleles at nine loci, indicating that they are completely reproductively isolated from each other.     

Efficacy and safety of insulin glulisine in patients with type 1 diabetes.

Insulin glulisine (glulisine), a human insulin analogue with a rapid-acting time-action profile, has been developed to fulfil the mealtime (bolus) insulin requirement in patients with diabetes. The aim of this multinational, multi-centre, controlled, open-label, randomized, parallel-group study was to compare the efficacy and safety of insulin glulisine (glulisine) to that of insulin lispro (lispro) in adults diagnosed with Type 1 diabetes. Of the 683 patients randomized, 672 received treatment (339 patients received glulisine, 333 patients received lispro). Over the 26-week study, a similar reduction in mean HbA1c occurred in both groups (adjusted mean change from baseline -0.14% in both groups). The basal insulin dose was relatively unchanged from baseline in the glulisine group but increased in the lispro group (glulisine: 0.12 IU vs. lispro: 1.82 IU; p = 0.0001). As a consequence, total daily insulin dose decreased in the glulisine group but increased in the lispro group (glulisine: -0.86 IU vs. lispro: 1.01 IU; p = 0.0123). There was no relevant difference between the two groups in the reporting of symptomatic hypoglycaemia (overall, nocturnal and severe). This study demonstrates that glulisine provides equivalent glycaemic control to lispro. The clinical relevance of any difference in total daily insulin dose remains to be established.